|
This device is used for treatment not diagnosis.The ventricular assist system is indicated for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure.The system is designed for in-hospital and out-of-hospital settings.The implantation of a vad is an invasive procedure requiring general anesthesia, median sternotomy, a ventilator and cardiopulmonary bypass.A user must fully consider the risks of this device with that of other treatment modalities before deciding to proceed with device implantation.These surgical procedures are associated with numerous risks.Infection, gastrointestinal bleed are known potential adverse event associated with the implantation of all vads as outlined in the instructions for use.Gastrointestinal bleeding has been identified as a known potential risk associated with use of all vads as outlined in the instructions for use (ifu).Known contributing factors to gi bleeding include individual patient comorbidities and pharmacological factors.The ifu addresses guidelines for optimal patient management, including therapeutic anticoagulation guidelines.Gi bleeding/av ms are known potential complications associated with all patients implanted with vads.With review of the available information there is no indication of any device malfunction or performance issues impacting the event.Although a definitive root cause cannot be determined, clinical, pharmacological, and patient factors including comorbidities are known possible contributors to the event.Heartware will submit a supplemental report when new facts arises which materially alters information submitted in a previous mdr report.Device remains implanted.
|
|
It was reported from the clinical study site that the patient was admitted on (b)(6) 2017 for upper gastrointestinal (gi) bleeding and bacteria gi infection with a urinary tract infection.Patient was stated to have been transfused 5 units of packed red blood cells (prbc's).Patient was also stated to have received angiectasia clipping, medication management, and antibiotics.Patient was stated to have been discharged on (b)(6) 2017.No additional information available.
|